<DOC>
	<DOCNO>NCT01085344</DOCNO>
	<brief_summary>Primary prophylaxis give less frequently initially , infusion frequency increase need ( Escalating Dose Prophylaxis ) , likely less expensive associate few complication standard prophylaxis reduce disability great degree intermittent therapy .</brief_summary>
	<brief_title>Canadian Hemophilia Prophylaxis Study</brief_title>
	<detailed_description>There 2 specific study objective . The first estimate incidence target joint bleeding patient severe hemophilia A treated ( primary prophylaxis ) Escalating Dose Prophylactic factor replacement . The second objective obtain accurate estimate direct indirect cost associate protocol use cost-effectiveness model ( compare Escalating Dose standard prophylaxis intermittent therapy ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( factor level le 2 % ) . Age great 1 year less equal 2.5 year . Normal joint use World Federation Hemophilia orthopedic scale . Normal radiographs joint bleed occur use World Federation Hemophilia radiographic scale . Platelet count &gt; 150,000 . Informed consent participate . Three clinically determine bleeds single elbow , knee ankle . Presence past history circulate inhibitor ( level â‰¥ 0.5 Bethesda Units ) . Family judge noncompliant local hemophilia clinic director . Competing risk ( symptomatic HIV infection , juvenile rheumatoid arthritis , metabolic bone disease , diseases know cause mimic arthritis . )</criteria>
	<gender>Male</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>30 Months</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>hemophilia , prophylaxis , cost effectiveness</keyword>
</DOC>